Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 8/2021 | Humacyte | PIPE | 175M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 5/2021 | Inari | Series D | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 3/2019 | Gencove | Seed Round | 3M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 3/2020 | Kallyope | Series C | 112M |
| 12/2022 | SonoThera | Series A | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2021 | IgGenix | Series A | 0 |
| 10/2017 | Cydan | Venture Round | 34M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 4/2018 | QurAlis | Seed Round | - |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 6/2018 | Cibus | Series C | 70M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 9/2021 | Disc Medicine | Series B | 90M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 3/2021 | StrideBio | Series B | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 12/2017 | Metacrine | Series B | 22M |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2022 | TRex Bio | Series A | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2022 | Dantari | Series A | 0 |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 9/2018 | Benson Hill | Series C | 65M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 7/2022 | Xilis | Series A | 0 |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Encodia | Series C | 75M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
